Grant: Operating Grant: SARS-CoV-2 variants supplement stream 1
Ottawa Hospital Research Institute
$50,000.00
COVID-19 Variant Supplement - Development of Vaccines to Prevent SARS-CoV-2 Infection of High Risk Individuals
EF 2020-21
Résumé
The physical-distancing strategy currently implemented in the Covid-19 pandemic in Canada has been very effective in preventing the vast majority of Canadians from being infected by SARS-CoV-2. This essential short-term strategy is saving lives, but paradoxically will leave most of our citizens without protective immunity and a recurrent outbreak is both predictable and likely without an effective Canadian vaccine strategy. A global effort has been initiated to identify an effective Covid-19 vaccine, testing a variety of vaccine platforms and strategies. Unfortunately, few of these are being developed, tested or manufactured in Canada leaving our population in a very perilous situation where our vaccine needs could be de-prioritized by foreign governments. This project is aimed at bringing together a multi-disciplinary team of scientists and clinicians to rapidly create and manufacture a vaccine to prevent a second wave of infections. We are using scientists and infrastructure, already available in Ottawa, Montreal, Calgary and the US (Covington Louisiana) to rapidly create, compare and contrast different vaccine strategies in animal models. Our best candidate will then be manufactured in a pure enough form to inject in humans. We will complete all of the data and regulatory documents to prepare an application to Health Canada to allow the initiation of a clinical trial in healthy volunteers.
Programme
Operating Grant: SARS-CoV-2 variants supplement stream 1
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Other
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
443276
Name
Bell John C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
COVID-19 Variant Supplement - Development of Vaccines to Prevent SARS-CoV-2 Infection of High Risk Individuals
Programtype2
Operating Grants
Orgnameinp2
Ottawa Hospital Research Institute
Cihramount2
$50,000
Cihrequipment2
$0
Programname2
Operating Grant: SARS-CoV-2 variants supplement stream 1
Keyworddelim
Covid-19; Epitopes; Immunity; Infection; Manufacturing; Pre-Clinical; Sars-Cov-2; Vaccine
Abstract
The physical-distancing strategy currently implemented in the Covid-19 pandemic in Canada has been very effective in preventing the vast majority of Canadians from being infected by SARS-CoV-2. This essential short-term strategy is saving lives, but paradoxically will leave most of our citizens without protective immunity and a recurrent outbreak is both predictable and likely without an effective Canadian vaccine strategy. A global effort has been initiated to identify an effective Covid-19 vaccine, testing a variety of vaccine platforms and strategies. Unfortunately, few of these are being developed, tested or manufactured in Canada leaving our population in a very perilous situation where our vaccine needs could be de-prioritized by foreign governments. This project is aimed at bringing together a multi-disciplinary team of scientists and clinicians to rapidly create and manufacture a vaccine to prevent a second wave of infections. We are using scientists and infrastructure, already available in Ottawa, Montreal, Calgary and the US (Covington Louisiana) to rapidly create, compare and contrast different vaccine strategies in animal models. Our best candidate will then be manufactured in a pure enough form to inject in humans. We will complete all of the data and regulatory documents to prepare an application to Health Canada to allow the initiation of a clinical trial in healthy volunteers.
Competitiondate
202102
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bell, John C; Ilkow, Carolina S; Lapointe, Réjean; Mahoney, Douglas J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $50,000~ $0~